Key statistics dashboard for Damora Therapeutics, Inc. (GLTO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Stock Data
| Price | $21.58 |
| Market Cap | $34M |
| Beta | 1.57 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.17 |
| Price / Book | 0.68 |
| P/S | 0.00 |
| P/FCF | -0.77 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 19.73 |
| Quick Ratio | 19.73 |
| Cash Ratio | 19.62 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 31.53 |
| Cash per share | 33.03 |
| FCF per share | -2.72 |
| Tangible Book Value per share | 31.53 |
| Dividend per share | 0.00 |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks